Guanidines pp 159-169 | Cite as

Studies on the Occurrence of Guanidino Compounds in Serum and Urine of Patients with Epilepsy, Neuronal Ceroid-Lipofuscinosis and Uremic Patients

  • Claus Munk Plum


Studies of guanidino compounds (GCs) in the serum and urine of patients with renal diseases are numerouns1–14.


Free Amino Acid Propionic Acid Succinic Acid Butyric Acid Epileptic Seizure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    B. D. Cohen, I. M. Stein and J. E. Bonas, Guanidinosuccinic aciduria in uremia,Am. J. Med., 45: 63 (1968).PubMedCrossRefGoogle Scholar
  2. 2.
    B. D. Cohen, Guanidinosuccinic acid in uremia, Arch. Intern. Med., 126: 846 (1970).CrossRefGoogle Scholar
  3. 3.
    B. D. Cohen, The origin and effect of guanidinosuccinic acidemia in uremia, 1st Annual Report of National Institute of Health Bethesda, Maryland, U.S.A. (1970).Google Scholar
  4. 4.
    H. Dobbelstein, H. H. Edel, M. Schmidt, G. Schubert und M. Weinzierl, Guanidinbernsteinsaure and Uramie, Kline. Wochenschr., 49: 348 (1971).CrossRefGoogle Scholar
  5. 5.
    S. Giovanetti, M. Biagnini and L. Cioni, Evidence that methylguanidine is retained in chronic renal failure, Experientia, 24: 341 (1962).CrossRefGoogle Scholar
  6. 6.
    T. Kikuchi, Y. Orita, A. Ando, H. Mikami, M. Fuji, A. Okada and H. Abe, Liquid-chromatographic determination of guanidino compounds in plasma and erythrocytes of normal persons and uremic patients, Clin. Chem., 27: 1899 (1981).Google Scholar
  7. 7.
    A. Mizuno, J. Mukawa, K. Kobayashi and A. Mori, Convulsive activity of taurocyamine in cats and rabbits,IRCS Med. Sci., 3: 35 (1975).Google Scholar
  8. 8.
    J. F. van Pilsum, R. P. Martin, E. Kiot and J. Hess, Determination of creatine, creatinine, arginine, guanidinoacetic acid, guanidine and methylguanidine in biological fluids, J. Biol. Chem., 222: 225 (1956).Google Scholar
  9. 9.
    M. Sasaki, M. Takahara and S. Natelson, Urinary guanidinoacetate guanidinosuccinate ratio: An indicator of kidney dysfunction, Clin. Chem., 19: 315 (1973).Google Scholar
  10. 10.
    J. Sawynok and J. K. Dawborn, Plasma concentration and urinary excretion of guanidine derivates in normal subjects and patients with renal failure, Clin. Exp. Pharin, Physiol., 2: 1 (1975).CrossRefGoogle Scholar
  11. 11.
    R. Shainkin, Y. Berkenstadt, Y. Giatt and G. M. Berlyne, An automated technique for the analysis of plasma guanidino acids, and some findings in chronic renal disease, Clin. Chem., 60: 45 (1975).Google Scholar
  12. 12.
    I. M. Stein, G. Perez, R. Johnson and N. N. B. Cuuuuings, Serum levels and urinary excretion of methylguanidine in chronic renal failure, J. Lab. Clin. Med., 77: 1020 (1971).PubMedGoogle Scholar
  13. 13.
    I. M. Stein, B. D. Cohen and R. S. Kornhauser, Guanidinosuccinic acid in renal failure, experimental azotemia and inborn errors of the urea cycle, New Engl. J. Med., 280: 926 (1973).Google Scholar
  14. 14.
    I. M. Stein and M. J. Micklus, Concentration in serum and urinary excretion of guanidine, 1-methylguanidine, 1,1-dimethyl-guanidine in chronic real failure, Clin. Chem., 19: 583 (1973).Google Scholar
  15. 15.
    S. Natelson, I. Stein and J. E. Bonas, Improvements of the method of separation of guanidino organic acids by column chromatography, Microchem. J., 8: 371 (1964).CrossRefGoogle Scholar
  16. 16.
    L. R. Baker and R. D. Marshall, A reinvestigation of methyl- guanidine concentration in sera from normal and uraemic subjects, Clin. Sci., 41: 563 (1973).Google Scholar
  17. 17.
    D. Jinnai, A. Sawai and A. Mori, y-Guanidinobutyric acid as convulsive substance, Nature, 212: 617 (1966).PubMedCrossRefGoogle Scholar
  18. 18.
    D. Jinnai, A. Mori, J. Mukawa, H. Ohkusu, M. Hosotani, A. Mizuno and L. C. Tye, Biochemical and physiological studies on guanidino compound induced convulsion, Jpn. Brain Physiol., 106: 27 (1969).Google Scholar
  19. 19.
    M. Matsumoto, K. Kobayashi, H. Kishikawa and A. Mori, Convulsive activity of methylguanidine in cats and rabbits, IRCS Med. Sci., 4: 65 (1976).Google Scholar
  20. 20.
    A. Mori, M. Akagi, Y. Katayama and Y. Watanabe, a-Guanidinoglutaric acid in cobalt-induced epileptogenic cerebral cortex of cats, J. Neurochem., 32: 603 (1980).CrossRefGoogle Scholar
  21. 21.
    M. Matsumoto, H. Kishikawa and A. Mori, Guanidino compounds in the sera of uremic patients and in sera and brain of experimental uremic rabbits, Biochem. Med., 16: 1 (1976).Google Scholar
  22. 22.
    M. Matsumoto and A. Mori, Effects of guanidino compounds on rabbits brain microsomal Na+ -K+ ATPase activity, J. Neurochem., 27: 635 (1976).PubMedCrossRefGoogle Scholar
  23. 23.
    A. Mori, M. Hosotani and L. C. Tye, Studies on brain guanidino compounds by automatic liquid chromatography, Biochem. Med., 10: 8 (1974).Google Scholar
  24. 24.
    A. Mori, M. Hiramatsu, T. Takahashi and M. Kohsaka, Guanidino compounds in rats organs, Comp Biochem. Phisol 51B: 143 (1975).Google Scholar
  25. 25.
    K. A. Szilagy, F. Lavinha and Y. ‘gardens, Study of free amino acidpattern in human cerebraospinal fluid along the cerebrospinal axis, Acta Neurol. Belg., 74: 329 (1974).Google Scholar
  26. 26.
    C. M. Plum, Renal handling of free amino acids in normal adults, in patients with epilepsy and in patients with Spielmeyer-Vogt-Batten’s disease, Dan. Med. Bull., 22: 194 (1975).Google Scholar
  27. 27.
    C. M. Plum, Studies on the occurrence of guanidino compounds in serum and urine of patients with epilepsy and patients with Spielmeyer-Vogt-Batten’s syndrome, Dan. Med. Bull., 27: 207 (1980).Google Scholar
  28. 28.
    J. Caries and G. Abravamel, Dosage automatic et simultane des acides amines et des guanidines, Bull. Soc. Chim. Biol., 52: 453 (1970).Google Scholar
  29. 29.
    C. M. Plum, Free amino acid levels in the cerebrospinal fluid of the normal humans and their variation in cases of epilepsy and Spielmeyer-Vogt-Batten disease. J. Neurochem., 23: 595 (1974).PubMedCrossRefGoogle Scholar
  30. 30.
    A. Mori and Y. Watanabe, Recovery rates for guanidino compound analyses and variance of measured values by different laboratories, Rinshoukagaku, 9: 183 (1980).Google Scholar
  31. 31.
    G. Perez, A. Rey, M. Micklus and I. Stein, Cation-exchange chromatography of guanidine derivates in plasma of patients with chronic renal failure, Clin. Chem., 22: 240 (1976).Google Scholar
  32. 32.
    H. I. Horowitz and B. D. Cohen, Defectice ADP-indued platelets factors-3-activation in uremia, Blood, 30: 331 (1967).PubMedGoogle Scholar
  33. 33.
    H. I. Horowitz, I. M. Stein, B. D. Cohen and J. G. White, Further studies on the platelet-inhibitory effect of guanidinosuccinic acid and its role in uremic bleeding, Am. J. Med., 49: 336 (1970).PubMedCrossRefGoogle Scholar
  34. 34.
    P. L. Balestri, M. Biaggini, P. Rindi and S. Giovanetti, Uremic toxins, Arch. Intern. Med., 126: 843 (1970).CrossRefGoogle Scholar
  35. 35.
    S. Giovanetti, L. Cioni, L. Balestri and M. Biagini, Evidence that guanidines and some related compounds cause haemolysis in chronic uraemia, Clin. Sci., 34: 141 (1968).Google Scholar
  36. 36.
    J. E. Bonas, B. D. Cohen and S. Natelson, Separation and estimation of certain guanidino compounds. Application to human urine, Microchem. J., 7: 63 (1963).Google Scholar
  37. 37.
    H. Borsook and J. W. Dubnoff, The formation of glycocyamine in animal tissue, J. Biol. Chem., 138: 389 (1941).Google Scholar

Copyright information

© Springer Science+Business Media New York 1985

Authors and Affiliations

  • Claus Munk Plum
    • 1
  1. 1.Kobenhavn NDenmark

Personalised recommendations